KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other financing activities: 2013-2022

Historic Other financing activities for Nektar Therapeutics (NKTR) over the last 1 years, with Mar 2022 value amounting to $750,000.

  • Nektar Therapeutics' Other financing activities changed negligibly% to $750,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $3.0 million, marking a year-over-year decrease of 97.81%. This contributed to the annual value of $750,000 for FY2022, which is 75.00% down from last year.
  • Per Nektar Therapeutics' latest filing, its Other financing activities stood at $750,000 for Q1 2022, which was down 0.00% from $750,000 recorded in Q4 2021.
  • Over the past 5 years, Nektar Therapeutics' Other financing activities peaked at $146.2 million during Q4 2020, and registered a low of $750,000 during Q1 2021.
  • Its 3-year average for Other financing activities is $25.0 million, with a median of $750,000 in 2022.
  • Data for Nektar Therapeutics' Other financing activities shows a maximum YoY crashed of 99.49% (in 2021) over the last 5 years.
  • Over the past 3 years, Nektar Therapeutics' Other financing activities (Quarterly) stood at $146.2 million in 2020, then plummeted by 99.49% to $750,000 in 2021, then remained steady at $750,000 in 2022.
  • Its last three reported values are $750,000 in Q1 2022, $750,000 for Q4 2021, and $750,000 during Q3 2021.